AUPH - Aurinia Executes On Expanding It's Intellectual Property Estate
Background on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (AUPH) is a small late-stage pharmaceutical company based out of British Colombia. They are currently conducting a large phase III trial testing their novel calcineurin inhibitor, Voclosporin, in the treatment of Lupus Nephritis. The agent impressed investors in its phase II trial, touting a complete and partial remission rate of 49% and 68%, a significant improvement over the placebo group taking the current standard of care, Cellcept, which recorded rates of 24% and 48%, respectively.
(Aurinia Pharmaceuticals Corporate Presentation, Phase II Aura Study)
Voclosporin’s approval in Lupus